Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells

The outcome of locally advanced cervical cancer (LACC) is dismal. Biomarkers are needed to individualize treatments and to improve patient outcomes. Here, we investigated whether coexpression of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) could be an outcome prognostic biomarker, and whether targeting both EGFR and HER3 with a dual antibody (MEHD7945A) enhanced ionizing radiation (IR) efficacy.

Source: International Journal of Radiation Oncology * Biology * Physics - January 16, 2020 Category: Radiology Authors: Laura Bourillon, Sylvain Demontoy, Alexis Lenglet, Alexandre Zampieri, Julien Fraisse, Marta Jarlier, Florence Boissi ère-Michot, Hélène Perrochia, Gauthier Rathat, Véronique Garambois, Nathalie Bonnefoy, Henri-Alexandre Michaud, Thierry Chardès, Die Tags: Biology Contribution Source Type: research